Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2024-11-08 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a request form for shareholders to receive annual and/or interim financial statements and corresponding MD&A. It does not contain any actual financial data, analysis, or report content. It is essentially a shareholder communication facilitating distribution of reports rather than the reports themselves. The document is short (2231 characters) and serves as a notification or request form. According to the rules, such documents that announce or facilitate access to reports but do not contain the reports themselves should be classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2024-11-08 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for PharmaTher Holdings Ltd. related to its Annual General Meeting (AGM) scheduled for November 29, 2024. It includes instructions for shareholders on how to vote, appoint proxies, and details resolutions to be approved at the meeting such as election of directors and appointment of auditor. The document is not the AGM presentation or materials themselves but the proxy form soliciting votes for the AGM. It is not a full report or financial statement but a voting solicitation document. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 4633 characters, which is consistent with a proxy form rather than a full report or announcement of a report.
2024-11-08 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2024. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3043 characters), and it is clearly a certification rather than a full interim report.
2024-10-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2024. It is a certification letter and does not contain the actual interim financial statements or substantive financial data. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3059 characters), and it is clearly a certification rather than a full report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2024-10-30 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM MANAGEMENT’S DISCUSSION AND ANALYSIS – QUARTERLY HIGHLIGHTS' for the three months ended August 31, 2024, dated October 24, 2024. It contains detailed discussion about the company's business operations, liquidity, capital resources, forward-looking statements, and references to unaudited condensed interim consolidated financial statements prepared under IFRS and International Standard 34 for interim financial reporting. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content and format align with an Interim / Quarterly Report, which includes actual financial data and management's discussion for a period shorter than a full fiscal year. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q1 2025
2024-10-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'PHARMATHER HOLDINGS LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS' for the three months ended August 31, 2024 and 2023. It contains detailed unaudited condensed interim consolidated financial statements including statements of financial position, loss and comprehensive loss, changes in equity, cash flows, and accompanying notes. The document explicitly states it is prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, and includes substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is a full interim report, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2024-10-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.